SVF
Level A· Stronger Clinical EvidenceMeta-analysis

Antifibrotic efficacy of adipose-derived mesenchymal stem cell-based therapeutic strategies in pre-clinical models of pulmonary fibrosis: A systematic review and meta-analysis.

Jabeen H., Ali M., Anum F., Najam S., Ali S., Saeed N.

Meta-analysis on Scar, published in Eur J Pharmacol (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Eur J Pharmacol (2026)
Country
Netherlands
Reported sample size
—
PMID
42119767
DOI
10.1016/j.ejphar.2026.178959

Abstract (original English)

Pulmonary fibrosis (PF) represents a heterogeneous group of chronic fibrotic lung diseases, characterized by excessive extracellular matrix (ECM) deposition and irreversible scarring, lacking curative therapies. This review highlights the antifibrotic efficacy of adipose-derived mesenchymal stem cells (AD-MSCs) in pre-clinical PF models. The review was prospectively registered in the PROSPERO database (registration number: CRD420251119193). Peer-reviewed experimental investigations/original articles were searched from Google Scholar, PubMed, and ScienceDirect up to April 2025. Risk of bias in in-vivo studies was assessed using SYRCLE's tool and for in-vitro studies, quality was evaluated with the QUIN tool. Results were synthesized narratively and quantitatively, using a random-effects model to pool mean differences (MD) with 95% confidence intervals for antifibrotic outcomes based on Ashcroft scores. Heterogeneity was assessed using Cochran's Q test and I 2 statistic. A comprehensive literature search yielded 397 studies, out of which 19 studies selected after title-based, abstract-based, and full text-based screening. Forest plot showed overall mean difference as -1.35 [95% CI: -3.19, 0.49]. Ashcroft scores were lower in treated groups compared with control group, but overall mean difference was not statistically significant (z = 1.44, p = 0.15), likely due to small number of

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
AnimalsMesenchymal Stem Cell TransplantationPulmonary FibrosisMesenchymal Stem CellsAdipose TissueDisease Models, AnimalHumans
Scar
View on PubMedDOI

Related research